Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.
Full Story
3,199,000 news articles indexed and analysed from 346 sources in 4 languages.
Articles and images are sorted, ranked and categorised automatically, placement is not intended to cause offence.
WireBeat accepts no liability for the content published by third parties.
English ¦ 
Spanish ¦ 
French ¦ 
German
© Accumudata Limited 2022 Release Version 1.22 Company Number: 12846061 All Rights Reserved.